Comparison clinical and metabolic effects of metformin and pioglitazone in polycystic ovary syndrome

Indian Journal of Endocrinology and Metabolism

Volumn 20, Issue 6, 2016, Pages 805-809

  Shahebrahimi, Karoon ^a   Jalilian, Nasrin ^a   Bazgir, Nasrin ^a   Rezaei, Mansour ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Insulin resistance; metformin; pioglitazone; polycystic ovary syndrome

Indexed keywords

EID: 84994477405     PISSN: 22308210     EISSN: 22309500     Source Type: Journal    
DOI: 10.4103/2230-8210.192925     Document Type: Article

References (22)

1. Hu L, Shen H, Wu QF, Tian L, Hu MH. Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. Clin Exp Obstet Gynecol 2014;41:288-92
2. Valsamakis G, Lois K, Kumar S, Mastorakos G. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS). Hormones (Athens) 2013;12:363-78
3. Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2009;70:233-7
4. Katsiki N, Hatzitolios AI. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: An update. Curr Opin Obstet Gynecol 2010;22:466-76
5. Ziaee A, Oveisi S, Abedini A, Hashemipour S, Karimzadeh T, Ghorbani A. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. Acta Med Indones 2012;44:16-22
6. Ibáñez L, Lopez-Bermejo A, Díaz M, Enríquez G, Del Río L, De Zegher F. Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: Increasing efficacy and persistent safety over 30 months. Gynecol Endocrinol 2010;26:869-73
7. Roe A, Hillman J, Butts S, Smith M, Rader D, Playford M, et al. Decreased cholesterol efflux capacity and atherogenic lipid profile in young women with PCOS. J Clin Endocrinol Metab 2014;99:E841-7
8. Vinaixa M, Rodriguez MA, Samino S, Díaz M, Beltran A, Mallol R, et al. Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy. PLoS One 2011;6:e29052
9. Du Q, Wang YJ, Yang S, Wu B, Han P, Zhao YY. A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. Curr Med Res Opin 2012;28:723-30
10. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: A meta-analysis. Clin Endocrinol (Oxf) 2011;74:332-9
11. Haydardedeoglu B, Simsek E, Kilicdag EB, Bagis T. Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2009;105:32-5
12. Geller DH, Pacaud D, Gordon CM, Misra M; of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the art review: Emerging therapies: The use of insulin sensitizers in the treatment of adolescents with polycystic ovary syndrome (PCOS). Int J Pediatr Endocrinol 2011;2011:9
13. Abdel Fattah G, Al Mohammady M, Hamed DA. Combined pioglitazone-metformin and clomiphene citrate versus metformin and clomiphene citrate in induction of ovulation in women with clomiphene citrate-resistant polycystic ovary syndrome. Middle East Fertil Soc J 2014;19:27-33
14. Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo-and hyperinsulinaemic obese patients with polycystic ovary syndrome. Hum Reprod 2003;18:1210-8
15. Ortega-Gonzalez C, Luna S, Hernández L, Crespo G, Aguayo P, Arteaga-Troncoso G, et al. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:1360-5
16. Naka KK, Kalantaridou SN, Kravariti M, Bechlioulis A, Kazakos N, Calis KA, et al. Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: A prospective randomized study. Fertil Steril 2011;95:203-9
17. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994;43:647-54
18. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, et al. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): A multicenter, double-blind, placebo-controlled randomized trial. J Clin Endocrinol Metab 2012;97:1492-500
19. Açbay O, Gündogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril 1996;65:946-9
20. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038-49
21. Glueck CJ, Moreira A, Goldenberg N, Sieve L, Wang P. Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Hum Reprod 2003;18:1618-25
22. Lerchbaum E, Schwetz V, Giuliani A, Obermayer-Pietsch B. Influence of a positive family history of both type 2 diabetes and PCOS on metabolic and endocrine parameters in a large cohort of PCOS women. Eur J Endocrinol 2014;170:727-39.